JPWO2022103221A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022103221A5 JPWO2022103221A5 JP2023525999A JP2023525999A JPWO2022103221A5 JP WO2022103221 A5 JPWO2022103221 A5 JP WO2022103221A5 JP 2023525999 A JP2023525999 A JP 2023525999A JP 2023525999 A JP2023525999 A JP 2023525999A JP WO2022103221 A5 JPWO2022103221 A5 JP WO2022103221A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- amino acid
- renal
- fusion protein
- reduction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200152247 | 2020-11-13 | ||
| KR10-2020-0152247 | 2020-11-13 | ||
| PCT/KR2021/016630 WO2022103221A1 (ko) | 2020-11-13 | 2021-11-15 | 치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023549323A JP2023549323A (ja) | 2023-11-24 |
| JPWO2022103221A5 true JPWO2022103221A5 (enExample) | 2024-11-25 |
Family
ID=81602509
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023525999A Pending JP2023549323A (ja) | 2020-11-13 | 2021-11-15 | 治療学的酵素融合タンパク質のファブリー病に起因する又は伴う腎臓疾患の予防及び治療用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230405093A1 (enExample) |
| EP (1) | EP4245311A4 (enExample) |
| JP (1) | JP2023549323A (enExample) |
| KR (1) | KR20220065719A (enExample) |
| CN (1) | CN116419760A (enExample) |
| AU (1) | AU2021378707A1 (enExample) |
| CA (1) | CA3196258A1 (enExample) |
| CO (1) | CO2023006437A2 (enExample) |
| IL (1) | IL302858A (enExample) |
| MX (1) | MX2023005580A (enExample) |
| WO (1) | WO2022103221A1 (enExample) |
| ZA (1) | ZA202304534B (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250040515A (ko) * | 2023-09-14 | 2025-03-24 | 주식회사 녹십자 | α-갈락토시다제 A의 융합단백질을 포함하는 신규한 동결 건조 제제 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| AU728657B2 (en) | 1996-03-18 | 2001-01-18 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| DK3345615T3 (da) * | 2010-03-01 | 2020-01-20 | Bayer Healthcare Llc | Optimerede monoklonale antistoffer mod inhibitor af vævsfaktoraktiveringsvejen (tfpi) |
| WO2015009052A1 (ko) * | 2013-07-16 | 2015-01-22 | 일동제약 주식회사 | 하이브리드 면역글로불린 fc와 효소의 융합단백질 |
| AR107483A1 (es) * | 2016-01-29 | 2018-05-02 | Hanmi Pharm Ind Co Ltd | Conjugado de enzimas terapéuticas |
| AU2018205891B2 (en) * | 2017-01-05 | 2024-11-07 | Protalix Ltd. | Therapeutic regimen for the treatment of fabry using stabilized alpha-galactosidase |
| TWI832818B (zh) * | 2017-07-07 | 2024-02-21 | 南韓商韓美藥品股份有限公司 | 新穎的治療性酵素融合蛋白及其用途 |
| FR3069340A1 (fr) * | 2017-07-21 | 2019-01-25 | Arkema France | Procede de controle de l'orientation des nano-domaines d'un copolymere a blocs |
| JP7403455B2 (ja) * | 2017-12-22 | 2023-12-22 | ハンミ ファーマシューティカル カンパニー リミテッド | 新規な構造を有する治療学的酵素融合タンパク質及びその用途 |
-
2021
- 2021-11-15 CN CN202180075093.2A patent/CN116419760A/zh active Pending
- 2021-11-15 EP EP21892388.6A patent/EP4245311A4/en active Pending
- 2021-11-15 WO PCT/KR2021/016630 patent/WO2022103221A1/ko not_active Ceased
- 2021-11-15 MX MX2023005580A patent/MX2023005580A/es unknown
- 2021-11-15 JP JP2023525999A patent/JP2023549323A/ja active Pending
- 2021-11-15 IL IL302858A patent/IL302858A/en unknown
- 2021-11-15 AU AU2021378707A patent/AU2021378707A1/en active Pending
- 2021-11-15 CA CA3196258A patent/CA3196258A1/en active Pending
- 2021-11-15 KR KR1020210156861A patent/KR20220065719A/ko active Pending
- 2021-11-15 US US18/036,580 patent/US20230405093A1/en active Pending
-
2023
- 2023-04-19 ZA ZA2023/04534A patent/ZA202304534B/en unknown
- 2023-05-16 CO CONC2023/0006437A patent/CO2023006437A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3528833B1 (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| ES2280083T3 (es) | Composiciones de proteinas de fusion ob y metodos. | |
| CN101553243B (zh) | 组织损伤修复中的基质细胞衍生因子1的蛋白酶抗性突变体 | |
| US20230348565A1 (en) | Methods of using activin receptor type ii variants | |
| JP2018070625A5 (enExample) | ||
| JP2023181445A5 (enExample) | ||
| JP2006516886A5 (enExample) | ||
| JP2025144567A (ja) | グルカゴン、及びｇｌｐ－１受容体及びｇｉｐ受容体二重アゴニストを含む組成物及びその治療学的使用 | |
| RU2005115477A (ru) | Нейтрализующие антитела против gdf-8 и их применение | |
| JP2006514607A5 (enExample) | ||
| KR20160003848A (ko) | 치료용 펩티드 | |
| CN106687478A (zh) | 新的抗人Tie‑2抗体 | |
| JP2023052614A5 (enExample) | ||
| RU2007119989A (ru) | Композиции, слитые конструкции и конъюгаты plad домена | |
| JP2023510864A (ja) | グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の持続型結合体の肺疾患の治療的使用 | |
| JPH08504210A (ja) | 結合生物活性ペプチドを使用した敗血症性ショックの治療 | |
| JPWO2022094299A5 (enExample) | ||
| JPWO2022103221A5 (enExample) | ||
| CA3251039A1 (en) | NEW CD200 FUSION PROTEINS | |
| JP2023524866A (ja) | 抗ｉｌ－３３抗体の処方物 | |
| JP5004408B2 (ja) | 抗ｈｉｖ組成物、その製造方法及び医薬 | |
| JPWO2023110983A5 (enExample) | ||
| JP2025506427A (ja) | 生物学的製剤の経口送達のための組成物 | |
| KR20220140443A (ko) | 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물 | |
| CN101341170B (zh) | 抗白介素-22结合蛋白的抗体及其用途 |